
|Articles|June 1, 2001
Bexarotene safe treatment for early-stage CTCL
Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















